SCHEMBL7744005

SCHEMBL7744005

O=S(=O)(CCCCCCCBr)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.56
HDAC8 Q9BY41 2/20 0.56
HDAC2 Q92769 2/20 0.56
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
HSD11B1 P28845 4/20 0.50
PSIP1 O75475 1/20 0.48
MMP3 P08254 2/20 0.45
MMP8 P22894 2/20 0.45
MMP13 P45452 2/20 0.45
MMP1 P03956 1/20 0.45
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096865 0.98 KEAP1 (0.54) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL4742560 0.92 PSIP1 (0.52) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL10626503 0.89 HDAC1 (0.65) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL576918 0.87 KEAP1 (0.63) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL1779667 0.83 PSIP1 (0.56) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL10629823 0.83 PSIP1 (0.61) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL21431073 0.82 PLCG1 (0.61) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL7295494 0.82 HDAC1 (0.57) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL7298807 0.82 HDAC1 (0.57) HDAC1HDAC8HDAC2HDAC3HDAC4
SCHEMBL7004939 0.81 KMT2A (0.46) HSD11B1MMP1ALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed